BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

Merck announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly improved long-term efficacy outcomes in patients

First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative potential...

September 14, 2022 | News

Merck to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients

Late-breaking data highlight 5-year survival results from Phase II study of the investigational IAP inhibitor xevinapant in the curative setting of unres...

September 08, 2022 | News

Breast Cancer AI Company FathomX Raises SGD$ 2.24 million in Pre-series A Funding

Through this funding, the company will be able to harness the full potential of its digital AI solution to read medical images including mammograms. The fu...

September 02, 2022 | News

Lunit AI Solution for Breast Cancer Detection Wins Commercial Approval in Taiwan

Lunit (KRX: 328130.KQ), a leading medical AI provider, today announced that it received commercial approval in Taiwan for Lunit INSIGHT MMG, the ...

August 26, 2022 | News

Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA)

lacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line...

August 21, 2022 | News

Sirnaomics Commence Treatment of Facial Squamous Cell Skin Cancer In Situ

Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi t...

August 19, 2022 | News

ZAODX World Conference on Early Detection of Cancer was successfully held in Guangzhou, China

In attendance were founders and representatives from over 100 leading companies and institutions involved in cancer screening and early detection from nume...

August 01, 2022 | News

AI-based Cancer Solution Pioneer Lunit Makes Market Debut

Lunit expects to raise approximately KRW 36.4 billion (US$ 28 million). Lunit intends to use the proceeds for R&D of its new AI products and ...

July 22, 2022 | News

New discovery in cancer progression paves way to combat cancer

The life span of a normal healthy cell is determined by telomeres, protective caps at the ends of chromosomes. Each time a cell divides, the telomeres beco...

July 21, 2022 | News

Urgent support needed following the pandemic's effect on cancer screening services

Dry July Foundation is urging Australians to dig even deeper this Dry July to help people affected by cancer. So many Australians could not access vital li...

July 15, 2022 | News

Tampa General Hospital Offers New Treatment Option for Recurrent Brain Cancer to Improve Quality of Life

Tampa General Hospital and USF Health Morsani College of Medicine physicians are the first in Hillsborough County to bri...

July 11, 2022 | News

ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment

TLX250-CDx, which has received "Breakthrough Designation" from the U.S. Food and Drug Administration (FDA)1, is being developed as an imaging agent for use...

July 11, 2022 | News

Seoul National University Hospital selects RayCare to advance oncology system

In April 2022 the carbon ion center at SNUH ordered RayStation treatment planning system, for use with their Toshiba Heavy Ion Therapy System. Th...

July 04, 2022 | News

Merck Opens €59 Million CDMO Facility to Address Demand for Critical Cancer Therapies

Expansion doubles production of the most highly potent active pharmaceutical ingredients (HPAPIs) Merck now one of industry’s largest manufacturer...

June 24, 2022 | News

Stay Connected